IQVIA beat on earnings, raised its full-year guidance, and booked a record $3.15 billion of new research work. The data-and-research engine behind the drug industry just had one of its cleanest quarters in years.
Most investors have never heard of $IQV, yet it sits at the center of how nearly every new medicine gets developed, tested, and sold. On July 28, IQVIA Holdings reported second-quarter results that beat expectations and raised its outlook for the year, and the stock surged in response. Revenue rose to $4.37 billion, adjusted earnings came in at $3.15 per share against a $3.04 estimate, and — the number that really stood out — its research division booked a record $3.15 billion of new work. The results were detailed on the company’s Q2 2026 earnings call and across the financial press.
IQVIA is a quiet compounder in one of the most durable corners of the economy: healthcare. This profile breaks down what the company reported, why the record bookings matter most, how a data-and-research business actually makes money, and the honest risks behind a stock that has already climbed sharply.
Company snapshot
- Company: IQVIA Holdings · Ticker: IQV (NYSE)
- Sector: Healthcare · Life-sciences data, analytics & contract research
- Headquarters: Durham, North Carolina · formed from the 2016 merger of IMS Health and Quintiles
- Chair & CEO: Ari Bousbib
- What it does: Runs clinical trials for pharma/biotech and sells the data, analytics, and technology that power drug development and commercialization
- This quarter: Record R&D bookings and a raised full-year outlook
Snapshot figures are widely reported company facts; the Q2 results are sourced below.
What actually happened
IQVIA delivered a clean, broad beat. Second-quarter revenue was $4.368 billion, up 8.7% year over year (8.5% in constant currency) and ahead of the ~$4.30 billion analysts expected. Adjusted EPS of $3.15 topped the $3.04 estimate. Notably, organic revenue growth reached 6% — roughly three times the pace of the prior-year period, a sign the business is re-accelerating.
On the strength of the quarter, the company raised its full-year 2026 guidance across the board: revenue to $17.275–$17.475 billion, adjusted EBITDA to $4.0–$4.05 billion, and adjusted EPS to $12.80–$13.00. Raising all three at once is a clear signal of confidence.
The numbers that moved it
| Metric | Q2 2026 | Context |
|---|---|---|
| Revenue | $4.37B | +8.7% YoY, beat ~$4.30B est. |
| Adjusted EPS | $3.15 | beat $3.04 est. |
| Organic growth | 6% | ~3x the prior-year pace |
| R&D net new bookings | $3.15B (record) | +19% YoY, 1.22x book-to-bill |
| FY26 revenue guide | $17.28–$17.48B | raised |
| FY26 EPS guide | $12.80–$13.00 | raised |
Sources: IQVIA Q2 2026 earnings call (Investing.com), TradingView, ChartMill, Yahoo Finance. Figures as reported.
The single most important figure is the record $3.15 billion of net new bookings in R&D Solutions, up 19%. Bookings are future revenue — contracts signed but not yet delivered — and a book-to-bill ratio of 1.22 means the company is winning new work faster than it is burning through its existing backlog. That is the leading indicator that this quarter’s strength is likely to persist.
Six months of tape
IQVIA has been a strong performer, with a gain of roughly 12% just this month heading into the print. A beat paired with a guidance raise and record bookings is the kind of quarter that reinforces a rally rather than exhausting it — though, as always, a stock that has already climbed sharply sets a higher bar for the quarters ahead.
Inside the business: how IQVIA makes money
IQVIA operates across the drug industry’s value chain in three broad areas. R&D Solutions — the standout this quarter — is its contract research organization, running the clinical trials that pharma and biotech companies need to bring a drug to market. This is where the record bookings landed, and it is a business built on long, multi-year contracts that provide unusually good visibility.
Technology & Analytics Solutions is the data engine: IQVIA holds one of the world’s deepest sets of healthcare and prescription data, and sells the analytics and software that help drugmakers decide what to develop and how to sell it. Contract Sales & Medical Solutions rounds it out, providing outsourced commercial and medical teams.
The reason the model is so durable: drug development is non-optional and enormously expensive, and companies increasingly outsource the trials, data, and analytics to a specialist that can do it better and cheaper. IQVIA is the largest such specialist, and it is now weaving AI through its trial design and analytics — a lever that can widen its lead.
Why this quarter matters
Three things stand out. First, the acceleration — organic growth running at three times the prior-year pace suggests the pharma-services slowdown that worried investors is giving way to renewed demand. Second, the record bookings and 1.22x book-to-bill say that strength is not a one-quarter blip; it is contracted future revenue. Third, raising guidance on revenue, profit, and EPS together signals management sees the momentum holding. For a business that had been growing more slowly, this quarter reads as an inflection.
Keeping it real
One honest note, because it belongs here: IQVIA’s customers are pharma and biotech companies, so its fortunes are tied to drug-industry R&D budgets and biotech funding, both of which can tighten in a tougher economic or policy environment. And the stock has already run — up double digits this month before the report — so a good deal of optimism is priced in. None of that undercuts an excellent quarter; it just means IQV is a high-quality name at a higher-expectations price.
What to watch next
The signals to track from here are concrete: whether R&D bookings and the book-to-bill ratio stay above 1.2 (the truest read on future growth), whether organic growth holds its accelerated pace, and how quickly AI-driven efficiencies show up in margins. Because IQVIA sits at the heart of drug development, its bookings also serve as a real-world barometer of how healthy pharma R&D spending is — and right now, that barometer is reading strong.
The bottom line
IQVIA beat, raised guidance across the board, and booked a record $3.15 billion of new research work — a quarter that shows demand re-accelerating in one of the most durable industries there is. It is the indispensable data-and-research partner to the drug industry, and it is now applying AI to widen that moat. It carries pharma-cycle risk and has already climbed a long way, so it is a high-expectations stock — but this was the kind of quarter that makes the quiet-compounder case louder.
Get the next Top Stock Pick in your inbox — free.
Recent Top Stock Picks
- Seagate Is Quietly Winning the AI Boom — Record Cash Flow and Blockbuster Guidance
- Kiniksa’s One-Drug Engine Just Beat Again — ARCALYST Revenue Up 55%, Guidance Raised
- Lockheed Martin Just Hit a Record $230B Backlog — and Raised Its Guidance to Match
- GE Vernova Just Nearly Doubled Its Cash-Flow Outlook — and a $176B Backlog Shows Why
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. TopStockPicks.co is not a registered investment advisor and is not a broker-dealer. TopStockPicks.co has NOT BEEN COMPENSATED for coverage of IQV. TopStockPicks.co and its affiliates or officers may buy and sell shares of IQV in the open market at any time without notice. TopStockPicks.co does not set price targets on securities. Always do your own due diligence and consult your financial advisor. Never invest into a stock discussed by TopStockPicks.co unless you can afford to lose your entire investment.
